1. Home
  2. NVCR vs GB Comparison

NVCR vs GB Comparison

Compare NVCR & GB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVCR
  • GB
  • Stock Information
  • Founded
  • NVCR 2000
  • GB 1980
  • Country
  • NVCR Switzerland
  • GB Switzerland
  • Employees
  • NVCR N/A
  • GB N/A
  • Industry
  • NVCR Medical/Dental Instruments
  • GB EDP Services
  • Sector
  • NVCR Health Care
  • GB Technology
  • Exchange
  • NVCR Nasdaq
  • GB Nasdaq
  • Market Cap
  • NVCR 1.4B
  • GB 1.5B
  • IPO Year
  • NVCR 2015
  • GB N/A
  • Fundamental
  • Price
  • NVCR $11.32
  • GB $7.40
  • Analyst Decision
  • NVCR Buy
  • GB Buy
  • Analyst Count
  • NVCR 7
  • GB 1
  • Target Price
  • NVCR $28.79
  • GB $6.00
  • AVG Volume (30 Days)
  • NVCR 1.7M
  • GB 31.0K
  • Earning Date
  • NVCR 07-24-2025
  • GB 08-27-2025
  • Dividend Yield
  • NVCR N/A
  • GB N/A
  • EPS Growth
  • NVCR N/A
  • GB 483.33
  • EPS
  • NVCR N/A
  • GB 0.38
  • Revenue
  • NVCR $630,160,000.00
  • GB $548,939,689.00
  • Revenue This Year
  • NVCR $6.15
  • GB $15.17
  • Revenue Next Year
  • NVCR $7.35
  • GB $6.50
  • P/E Ratio
  • NVCR N/A
  • GB $19.59
  • Revenue Growth
  • NVCR 14.58
  • GB 20.26
  • 52 Week Low
  • NVCR $10.91
  • GB $4.29
  • 52 Week High
  • NVCR $34.13
  • GB $8.00
  • Technical
  • Relative Strength Index (RSI)
  • NVCR 25.05
  • GB 50.95
  • Support Level
  • NVCR $10.91
  • GB $7.37
  • Resistance Level
  • NVCR $12.38
  • GB $7.41
  • Average True Range (ATR)
  • NVCR 0.93
  • GB 0.02
  • MACD
  • NVCR -0.49
  • GB 0.01
  • Stochastic Oscillator
  • NVCR 6.13
  • GB 74.03

About NVCR NovoCure Limited

NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

About GB Global Blue Group Holding AG

Global Blue Group Holding AG offers a seamless shopping and payment journey for tourists and also provides a wide range of Added-Value Payment Solutions for all the stakeholders involved, including retailers and international shoppers. The company connect thousands of retailers, acquirers, and hotels with nearly 80 million consumers across more than 50 countries, in three industries: Tax Free Shopping, Payments and Post-Purchase solutions.

Share on Social Networks: